SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX)

NEW YORK, Jan. 31, 2018 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MabVax Therapeutics Holdings, Inc. (“MabVax” or the “Company”) (NASDAQ: MBVX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/mbvx.

The investigation concerns whether MabVax and certain of its officers and/or directors have violated Federal Securities Laws.

On January 30, 2018, MabVax revealed “that it received notice that the Securities and Exchange Commission (“SEC”) was conducting an investigation and examination pursuant to Section 8(e) of the Securities Act of 1933, as amended, relating to certain of the Company’s registration statements (and amendments thereto).” Following this news, MabVax stock dropped during intraday trading on January 30, 2018.

If you are aware of any facts relating to this investigation, or purchased MabVax shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/mbvx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]